9:28 AM
Feb 16, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Neurim's PedPRM meets in Phase III for insomnia in children with autism

In October, Neurim Pharmaceuticals Ltd. (Tel Aviv, Israel) reported data from a Phase III trial in 125 children ages 2-18 with autism or neurogenetic diseases and insomnia showing that PedPRM melatonin met the primary endpoint of increasing parent-reported total sleep time vs. placebo (p=0.034). Specifically, PedPRM...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >